ArticleToxicology reports2026
Neuroprotective effects of agomelatine in a D-galactose-induced hippocampal aging model.
Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low melatonin levels are common features of both aging and depression, conditions associated with hippocampal degeneration resulting from neuronal damage, as well as a decline in the survival of various hippocampal cell types, including neural stem cells (NSCs) that generate new neurons. The novel antidepressant agomelatine (Ago), a melatonin (MT) receptor agonist, may enhance hippocampal cell survival. Male Wistar rats were intraperitoneally injected with D-galactose (D-gal, 100 mg/kg) for 14 weeks to induce aging. During the last 4 weeks, they received either Ago (40 mg/kg) or melatonin (10 mg/kg) as a positive control. Our results showed that D-gal-induced hippocampal aging led to increased expression of hypoxia-inducible factor 1 alpha (HIF-1α), which was consistent with elevated vascular endothelial growth factor (VEGF) levels. Treatment with either Ago or melatonin decreased HIF-1α and VEGF levels. Furthermore, Ago and melatonin treatment stimulated phosphorylation of VEGFR2 in the hippocampus, which contains NSCs. This activation is associated with stimulation of the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) survival pathway and increased production of brain-derived neurotrophic factor (BDNF). The NSC population (nestin-positive cells) increased, as did the population of immature neurons (doublecortin (DCX)- and Tuj1-positive cells. Ago and melatonin treatments also enhanced synaptic function, as indicated by elevated postsynaptic density protein 95 (PSD95) and synaptophysin, both of which are associated with spatial memory measured using the Morris water maze (MWM) test. Our findings demonstrate that Ago improves memory function in aging rats, potentially through enhanced hippocampal survival, mediated by increased pVEGFR2, which is correlated with the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.